...
首页> 外文期刊>Veterinary Immunology and Immunopathology >Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia
【24h】

Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia

机译:重组支原体支原体蛋白引发针对传染性牛胸膜肺炎的保护性免疫反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Mycoplasma mycoides subsp. mycoides (Mmm) is the causative agent of contagious bovine pleuropneumonia (CBPP), a devastating respiratory disease mainly affecting cattle in sub-Saharan Africa. The current vaccines are based on live-attenuated Mmm strains and present problems with temperature stability, duration of immunity and adverse reactions, thus new vaccines are needed to overcome these issues. We used a reverse vaccinology approach to identify 66 Mmm potential vaccine candidates. The selection and grouping of the antigens was based on the presence of specific antibodies in sera from CBPP-positive animals. The antigens were used to immunize male Boran cattle (Bos indicus) followed by a challenge with the Mmm strain Afade. Two of the groups immunized with five proteins each showed protection after the Mmm challenge (Groups A and C; P 0.05) and in one group (Group C) Mmm could not be cultured from lung specimens. A third group (Group N) showed a reduced number of animals with lesions and the cultures for Mmm were also negative. While immunization with some of the antigens conferred protection, others may have increased immune-related pathology. This is the first report that Mmm recombinant proteins have been successfully used to formulate a prototype vaccine and these results pave the way for the development of a novel commercial vaccine. (C) 2016 Elsevier B.V. All rights reserved.
机译:支原体支原体亚种霉菌毒素(Mmm)是传染性牛胸膜肺炎(CBPP)的病原体,牛胸膜肺炎是一种破坏性呼吸道疾病,主要影响撒哈拉以南非洲的牛。当前的疫苗基于减毒的活mmmm菌株,并且存在温度稳定性,免疫持续时间和不良反应的问题,因此需要新的疫苗来克服这些问题。我们使用了反向疫苗学方法来识别66毫米潜在的候选疫苗。抗原的选择和分组基于CBPP阳性动物血清中特异性抗体的存在。抗原用于免疫雄性Boran牛(Bos indicus),然后用Mmm菌株Afade攻击。用五种蛋白质免疫的两组中的每组在Mmm攻击后均显示出保护作用(A和C组; P <0.05),而在一组(C组)中,无法从肺标本中培养Mmm。第三组(N组)显示出具有损伤的动物数量减少,并且Mmm的培养物也为阴性。虽然使用某些抗原进行免疫可提供保护,但其他抗原可能会增加免疫相关的病理。这是关于Mmm重组蛋白已成功用于配制原型疫苗的首次报道,这些结果为新型商业疫苗的开发铺平了道路。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号